- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Next-Generation Sequencing testing has transformed the way clinicians evaluate cancer by enabling broad molecular analysis from a single specimen.
Compared with narrower testing strategies, NGS testing can assess multiple classes of genomic alterations at the same time, helping physicians obtain a more complete molecular picture that may support diagnosis, prognostic assessment, biomarker identification, therapy selection, and clinical trial consideration. In modern oncology, NGS testing plays an increasingly important role when clinically actionable information may extend beyond a limited single-gene approach.
Next-Generation Sequencing testing allows multiple clinically relevant alterations to be analyzed in parallel, including mutations, insertions and deletions, copy number changes, and, when RNA is included, gene fusions and expression-related findings.
In oncology practice, tissue can be limited. NGS testing helps maximize the value of available specimen material by evaluating many relevant biomarkers within a single testing workflow rather than relying on multiple sequential assays.
Because treatment planning may depend on a wide range of biomarkers, next-gen sequencing testing can provide physicians with a more comprehensive molecular framework for therapy selection, prognostic evaluation, and personalized treatment planning.
Next-Gen testing can be especially valuable in complex or diagnostically challenging cases where broader profiling may help clarify disease biology, identify uncommon but relevant alterations, or support additional stratification beyond routine pathology alone.
Next-Generation Sequencing (NGS) is used across multiple oncology settings, including solid tumors, hematologic malignancies, and liquid biopsy applications, making it a versatile approach for modern molecular diagnostics.
For many clinical scenarios, starting with NGS testing can be more efficient than ordering a series of narrower tests over time. A comprehensive Next-Generation Sequencing testing strategy may help identify relevant biomarkers earlier, reduce delays associated with reflex testing, and provide a stronger foundation for therapeutic planning. As oncology care becomes increasingly biomarker-driven, next-gen testing supports a more informed and clinically integrated diagnostic workflow.
Next-Generation Sequencing (NGS) has become an essential part of modern cancer diagnostics because it enables broad molecular analysis from a single specimen. In oncology, NGS testing supports a more comprehensive understanding of tumor biology by helping identify clinically relevant genomic alterations that may inform diagnosis, prognosis, therapy selection, and precision medicine strategies.
Unlike narrower testing approaches that evaluate only one or a few biomarkers at a time, Next-Generation Sequencing testing can assess multiple types of genomic alterations within a single workflow. This broader molecular view helps clinicians identify mutations, copy number changes, and other relevant biomarkers more efficiently, while also supporting a more complete characterization of disease.
In many oncology settings, clinically meaningful information extends beyond a limited single-marker approach. NGS testing offers a more comprehensive strategy by helping physicians evaluate a broader set of potential drivers, resistance mechanisms, and treatment-relevant biomarkers. This can be especially valuable in cases where therapeutic planning depends on more than one molecular feature.
Tissue availability is often limited in cancer care. Next-gen testing helps make better use of available specimen material by reducing the need for multiple sequential tests. A more consolidated testing strategy may also improve efficiency for pathology and oncology workflows by minimizing repeated procedures and preserving valuable tissue for additional clinical needs.
Time matters in oncology, particularly when treatment decisions depend on molecular results. A well-designed Next-Generation Sequencing testing workflow can help accelerate access to clinically relevant information and reduce delays associated with stepwise testing approaches. Faster access to molecular insights may support earlier treatment planning and more confident next-step decisions.
The value of NGS testing lies not only in detecting molecular alterations, but in helping place those findings into meaningful clinical context. When interpreted alongside pathology, disease subtype, treatment history, and other clinical factors, Next-Generation Sequencing can contribute to more informed decisions around targeted therapy, immunotherapy, prognostic assessment, and clinical trial consideration.
As oncology becomes increasingly biomarker-driven, Next-Generation Sequencing testing continues to play a growing role in precision medicine. Its strength is in combining breadth, efficiency, and clinical relevance within a single molecular testing framework, making it an important diagnostic tool across both common and complex cancer presentations.
The following references support the broader role of Next-Generation Sequencing (NGS) in cancer diagnostics, molecular profiling, and precision medicine.
References
Mardis, E. R., et al. (2020). Next-Generation Sequencing for Cancer Diagnostics: A Review.
National Cancer Institute (NCI). (2021). Cost Analysis of Next-Generation Sequencing in Cancer Diagnostics.
Wang, Y., et al. (2022). Impact of Next-Generation Sequencing on Time to Treatment Initiation in Cancer Patients.
Next-Generation Sequencing (NGS) is a high-throughput molecular testing method that enables simultaneous analysis of multiple genomic targets. In cancer care, NGS testing is used to detect clinically relevant molecular alterations that may support diagnosis, prognosis, targeted therapy selection, and precision medicine strategies.
NGS testing is important because cancer is often driven by multiple molecular alterations rather than a single biomarker. Next-Generation Sequencing testing helps physicians evaluate a broader range of potentially relevant findings in one workflow, which can improve biomarker detection and support more personalized treatment decisions.
Depending on the assay design, next-gen sequencing testing can detect single-nucleotide variants, insertions and deletions, copy number alterations, and, with RNA-based analysis, gene fusions, exon-skipping events, and expression-related findings. The exact scope depends on the specific test being ordered.
RNA analysis can add clinically meaningful information that may not be captured through DNA analysis alone. In many settings, combining DNA and RNA within NGS testing can improve detection of fusions, transcript-level abnormalities, and other biologically relevant findings that may affect treatment planning.
In many oncology settings, NGS testing offers a broader and more efficient approach than sequential single-gene testing, especially when multiple biomarkers may be clinically relevant. Single-gene tests may still have a role in selected scenarios, but Next-Generation Sequencing testing is often preferred when comprehensive profiling is needed.
A physician may consider next-gen sequencing testing when comprehensive molecular profiling could influence diagnosis, prognosis, treatment selection, resistance assessment, or clinical trial eligibility. It is particularly useful when the disease context suggests that multiple biomarkers may be relevant rather than one isolated target.
Yes. NGS testing is a core tool in precision medicine because it helps identify molecular alterations that may inform targeted therapies, immunotherapy strategies, and biomarker-driven clinical decision-making. Next-Generation Sequencing provides the broad molecular insight needed to align treatment more closely with the biology of the patient’s disease.
As cancer care continues to evolve, Next-Generation Sequencing testing offers physicians a more comprehensive way to evaluate tumor biology and identify clinically meaningful biomarkers. By supporting broader genomic analysis, NGS testing helps clinicians move beyond limited testing strategies and toward a more informed, efficient, and precision-focused approach to molecular oncology.
Learn how GTC’s genomic testing solutions use Next-Generation Sequencing (NGS) to support comprehensive molecular profiling across solid tumors, hematologic malignancies, and liquid biopsy applications.
